Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice

British Journal of Cancer

Volumn 75, Issue 2, 1997, Pages 169-177

  Chang, C W ^a   Barber, L ^a   Ouyang, C ^a   Masin, D ^b   Bally, M B ^b   Madden, T D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Anti tumour efficacy; Biodistribution; Liposome; Mitoxantrone; Polyethylene glycol lipid

Indexed keywords

DRUG CARRIER; LIPID; LIPOSOME; MITOXANTRONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; CONTROLLED STUDY; DRUG CAPSULE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RELEASE; DRUG UPTAKE; ENCAPSULATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN;

EID: 0031027945     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.28     Document Type: Article

References (42)

1. Allen TM (1994) Long circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharm Sci 15: 215-220
2. Allen TM, Hansen C, Martin F, Redemann C and Yan-young A (1991) Liposomes containing synthetic lipid derivatives of polyethylene glycol show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1066: 29-36
3. Bally MB, Masin D, Nayar R, Cullis PR and Mayer LD (1994) Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumour-bearing mice. Cancer Chemother Pharmacol 34: 137-146
4. Batist G, Panasci L, Gruner P, Leyland-Jones P, Pilkiewicz F and Haccoun L (1992) Phase II study of liposomal doxorubicin (TLC D-99) in metastatic breast cancer. Proc Am Soc Clin Oncol 11: 82
5. Boman NL, Masin D, Mayer LD, Cullis PR and Bally MB (1994) Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumor. Cancer Res 54: 2830-2833
6. Chonn A, Semple SC and Cullis PR (1992) Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem 267: 18759-18765
7. Cullis PR, Mayer LD, Bally MB, Madden TD and Hope MJ (1989) Generating and loading of liposomal systems for drug-delivery applications. Adv Drug Del Rev 3: 267-282
8. Fiske CM and Subbarow Y (1925) The colourimetric determination of phosphorus. J Biol Chem 66: 375-400
9. Forseen EA (1988) Chemotherapy with anthracycline liposomes. In Liposomes as Drug Carriers, Gregoriadis G (ed.) pp. 355-364. John Wiley and Sons: Chichester.
10. Funalo K, Yoda R and Kiwada H (1992) Contribution of complement system to destabilization of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasma. Biochim Biophys Acta 1103: 198-204
11. Gabizon AA (1992) Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 52: 891-896
12. Gabizon A, Dagan A, Goren D, Barenholz Y and Fuks Z (1982) Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res 42: 4734-4739
13. Gabizon A and Papahadjopoulos D (1988) Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 85: 6949-6953.
14. Gabizon A, Shiota R and Papahadjopoulos D (1989) Pharmacokinetics and tissue distribution of doxorubcin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst 81: 1484-1488
15. Hope MJ, Bally MB, Webb G and Cullis PR (1985) Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta 812: 210-216
16. Huang L (1983) Liposome-cell interactions in vitro. In Liposomes from Biophysics to Therapeutics, Ostro MJ (ed.). Marcel Dekker: New York
17. Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ and Papahadjopoulos D (1992) Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 52: 6774-6781
18. Klibanov AL, Maruyama K, Torchilin VP and Huang L (1990) Amphipathic polyethylene glycols effectively prolong the circulation time of liposomes. Febs Lett 268: 235-237
19. Madden TD, Tilcock CPS, Wong K and Cullis PR (1988) Spontaneous vesiculation of large multilamellar vesicles composed of saturated phosphatidylcholine and phosphatidylglycerol mixtures. Biochemistry 21: 8724-8730
20. Madden TD, Harrigan PR, Tai LCL, Bally MB, Mayer LD, Redelmeier TE, Loughrey HC, Tilcock CPS, Reinish LW and Cullis PR (1990) The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem Phys Lipids 53: 37-46
21. Maruyama K, Unezaki S, Yuda T, Ishida O, Takahashi N, Suyinaka A, Huang L and Iwatsuru M (1994) Enhanced delivery and antitumor effect of doxorubicin encapsulated in long-circulation liposomes. J Liposome Res 4: 143-165
22. Mayer LD, Hope MJ, Cullis PR and Janoff AJ (1986a) Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles. Biochem Biophys Acta 817: 193-200
23. Mayer LD, Bally MB and Cullis PR (1986b) Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta 857: 123-126
24. Mayer LD, Tai LCL, KO DSC, Masin D, Ginsberg RS, Cullis PR and Bally MB (1989) Influence of vesicle size, lipid composition and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 49: 5922-5930
25. Mayer LD, Bally MB, Loughrey H, Masin D und Cullis PR (1990a) Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res 50: 575-579
26. Mayer LD, Bally MB, Cullis PR, Wilson SL and Emerman JT (1990b) Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett 53: 183-190
27. Mayer LD, Cullis PR and Bally MB (1994) The use of transmembrane pH gradient-driven drug encapsulation in the pharmacodynamic evaluation of liposomal doxorubicin. J Liposome Res 4: 529-553
28. Morgan JR, Williams LA and Howard CB (1985) Technetium-labelled liposome imaging for deep-seated infection. Br J Radiol 58: 35-39
29. Northfield DW, Russel J, Anderson M, Lang J and Volberding PA (1993) Pharmacokinetics, tumor localization and safety of Doxil (liposomal doxorubicin) in AIDS patients with Karposi's sarcoma (AIDS-KS). Proc Am Soc Clin Oncol 12: 51
30. Ogihara I, Kojimi S and Jay M (1986) Differential uptake of gallium-67-labelled liposomes between tumors and inflammatory lesions in rats. J Nucl Med 27: 1300-1307
31. Olson F, Mayhew E, Maslow D, Rustum Y and Szoka F (1982) Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. Eur J Cancer Clin Oncol 18: 167-176
32. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C and Martin FJ (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and anti-tumor therapeutic efficacy. Proc Natl Acad Sci USA 88: 11460-11464
33. Pestalozzi B, Schwendener R and Sauter C (1992) Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. Ann Oncol 3: 445-449
34. Pick U (1981) Liposomes with a large trapping capacity prepared by freezing and thawing sonicated phospholipid mixtures. Arch Biochim Biophys 212: 186-194
35. Presant CA, Proffitt RT, Smith JD and Mckenna RJ (1986) Evidence for solid tumor accumulation of intravenously injected lipid vesicles (LV) in patients. Proc Am Acad Cancer Res 27: 158
36. Rahman A, Kessler A, More N, Sikic B, Rowden G, Woolley P and Schein PS (1980) Liposomal protection of adriamycin-induced cardiotoxicity in mice. Cancer Res 40: 1532-1537
37. Schwendener RA, Fiebig HH, Berger MR and Berger DP (1991) Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy. Cancer Chemother Pharmacol 27: 429-439
38. Schwendener RA, Horber DH, Rentsch K, Hanseler E, Pestalozzi B and Sauter C (1994) Preclinical and clinical experience with liposome-encapsulated mitoxantrone. J Liposome Res 4: 605-639
39. Shenkenberg TD and Von Hoff DD (1986) Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med 105: 67-81
40. Smith IE (1983) Mitoxantrone (Novantrone): a review of experimental and early clinical studies. Cancer Treat Rev 10: 103-115
41. Vaage J, Mayhew E, Lasic DD and Martin F (1992) Therapy of primary and metastatic mouse mammary carcinoma with doxorubicin encapsulated in long circulating liposomes. Int J Cancer 51: 942-948
42. Williams BD, O'Sullivan MM, Saggu GS, Williams KE, Williams LA and Morgan JR (1986) Imaging in rheumatoid arthritis using liposomes labelled with technetium. Br Med J 293: 1143-1144